KiraGen Bio Selected for Recode Edge ’25 Cohort, in the Running for $2M in Follow-On Investment

We’re excited to announce that KiraGen Bio has been selected as one of ten companies in the Recode Edge ’25 cohort—a highly competitive pre-seed program designed to back early-stage teams using artificial intelligence to solve major healthcare challenges.

Out of more than 200 applicants, Recode Ventures selected just ten companies that exemplify bold thinking, novel technology, and the potential to reshape the future of health. As part of the program, we’ll receive hands-on support from the Recode team and partners including Eli Lilly and Company, Amazon Web Services (AWS), OpenAI, DLA Piper, and JPMorgan Chase. We’ll also attend an exclusive bootcamp in Chicago alongside other trailblazing startups in healthcare AI.

Being part of this cohort puts us in the running for up to $2 million in follow-on investment, which would be catalytic as we continue building out KiraLOGIC—our AI-driven platform that identifies optimal multiplex gene editing combinations to overcome tumor microenvironment (TME) suppression in solid tumors.

At KiraGen, we’re focused on engineering next-generation cell therapies starting with glioblastoma (GBM), one of the most challenging and underserved cancers. Our team—drawn from leaders at Beam Therapeutics, Bluebird Bio, and Harvard—knows what it takes to bring cutting-edge science into the clinic. The Recode Edge program is an incredible opportunity to accelerate that mission.

We’re honored to be part of this inspiring group and grateful to Recode and their partners for believing in our vision.

Let’s build.